Sacubitril-Valsartan: A Cost-Effective Solution for Heart Failure Management

By Staff Writer

October 7, 2023

A New Class IA Recommendation for Heart Failure Treatment

Heart failure, a major cause of hospital admissions in the U.S., comes with high morbidity, mortality, and financial costs. Recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF) have given rise to new disease-modifying therapies. One such novel angiotensin receptor neprilysin inhibitor (ARNI) is sacubitril-valsartan.

The PARADIGM-HF clinical trial found that sacubitril-valsartan reduced the risk of cardiovascular death or hospitalization due to heart failure (HF), among ambulatory patients with an HFrEF of 40% or less. This makes it a highly cost-effective treatment option.

Broadening the Scope of Sacubitril-Valsartan

In February 2021, the U.S. Food and Drug Administration expanded the labelling of sacubitril-valsartan to include all adult patients with chronic HF. This decision was based on the understanding that the benefits are most evident in patients with left ventricular ejection fraction (LVEF) below normal. However, the upper bound of below-normal EF is not well defined.

A recent economic evaluation of treatment with sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) in patients with HF across a broader range of EFs found the treatment to be of high economic value for patients with EF≤50%. It showed intermediate value up to an EF of 60% or less before accounting for any price concessions that payers may receive.

Commentary from Cohen at al., mentioned that the economic value of sacubitril-valsartan is comparable to sodium-glucose cotransporter 2 inhibitors (SGLT2is). Both are dependent on drug price. SGLT2is were estimated to be intermediate value costing $126 500 and $139 000 per quality-adjusted life year in those with LVEFs of 40% to 49% and 50% to 59%, respectively. However, these analyses do not consider the affordability of the medications for individuals. Economic assessments of these novel medications suggest they could add billions to US healthcare spending. Without efforts to lower drug prices, the use of costly, intermediate- to low-value care may be reinforced.

Conclusion
Sacubitril-valsartan increases quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio consistent with high economic value for patients inclusive of reduced and mildly reduced EFs (≤50%). The data analysis of 13,264 total patients showed that for those with EFs of 60% or less, sacubitril-valsartan could potentially add 0.53 quality-adjusted life-years (QALYs). This would come at an incremental lifetime cost of $40,892 compared to RASi, resulting in an ICER of $76,852 per QALY. Therefore, it is estimated to be of at least intermediate value when using the current undiscounted wholesale acquisition cost price across a broad HF population with EFs below normal, when below normal is defined as an EF of 60% or less.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.